FDA Accepts ANI’s Refiled Cortophin Gel
For Indications Including Multiple Sclerosis, Rheumatoid Arthritis And Nephrotic Syndrome
ANI Pharmaceuticals has announced that the refiled sNDA for its Cortrophin Gel has been accepted by the FDA with a target action date of 29 October 2021. The company said that it was continuing to strengthen its rare disease business leadership team and overall organization to drive the Cortrophin Gel launch preparation.
